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ABSTRACT: Crystallization as the most widespread purification,
separation, and morphology-determining method is a critical
technology that could be made safer and more economical by
using continuous crystallization alternatives. Accordingly, this
study aims to develop the continuous crystallization method for
direct processing of a flow reaction mixture of acetylsalicylic acid
(ASA) and to provide pure, homogeneous crystalline products for
further formulation steps. The solid−liquid separation and the
purification of the acetylsalicylic acid from the multicomponent
mixture were accomplished in a single stage mixed suspension
mixed product removal (MSMPR) continuous crystallizer
equipped with an overflow and an inner buffer element to ensure
the representative withdrawal of the product suspension. The effect of process parameters such as the operating temperature and the
length of residence time (RT) on product quality and quantity were studied at two and three levels, respectively. Investigating these
parameters, we found that higher operating temperatures (25 °C) and longer residence time (47 min) favor appropriate purity
(>99.5%), and narrow crystal size distribution. By reducing the operating temperature (2.5 °C), the yield improved slightly
(approximately 77%) and polydisperse products were characterized. The developed crystallization process can link the flow synthesis
with the continuous formulation, and consequently serves a further step toward end-to-end production.
1. INTRODUCTION
Changing of batch processes to continuous technologies has
become an urgent issue in the pharmaceutical industry since
the early 2000s. Batch manufacturing is widespread, while
using continuous technologies is on the elementary stage
compared to other fields with the same production volume.1
The slow conversion to continuous techniques could be
explained by the complexity of the procedures and the former
conservative regulating attitude of the authorities, among other
causes. In recent years, recognizing the many advantages of
continuous manufacturing, the regulatory bodies in coopera-
tion with the pharmaceutical companies have been urging the
conversion to continuous processes.2−4 Several synthetic and
formulation procedures have been accomplished in a
continuous mode; however, only a few studies have dealt
with the direct connection of these steps.5,6 Thus, linking the
flow synthesis with the continuous formulation procedures
using continuous crystallization technology (for direct isolation
and purification of the flow reaction mixture) is a remarkable
stage toward end-to-end manufacturing.
The quality of products manufactured by conventionally
used batch processes can change from batch to batch.7 In
contrast, by implementing the continuous crystallization
methods, the production of solid active pharmaceutical
ingredients (APIs) could be accomplished in steady state
using a much smaller size of equipment. Choosing the right
parameters, the quality and quantity of the crystals could be
affected, and thus it makes the product features designed.
Therefore, in many cases, the production chain is shortened by
the elimination of various formulation processes. All of these
differences result in a decrease in investment costs by
approximately 20%.3
The kinetics of crystallization determines the continuous
crystallization technique and equipment to choose.7,8 Pro-
cesses with slower conversion require longer residential time,
which could be accomplished mainly in a continuous stirred
tank crystallizer. The most common type of continuous tank
crystallizer is the mixed suspension mixed product removal
(MSMPR) reactor system,9,10 which could be operated in a
single stage or in multiple stages. If the crystallization kinetics
is fast, then plug flow crystallizers11 can be preferred ensuring
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efficient mixing and short residence time.7,12,13 MSMPR, a key
device in the continuous crystallization studies, is practically
the same instrument that is utilized in batch processes.4,14,15 In
parallel, it performs the difficulties attached to batch
equipment as well. Previous studies have reported simplicity,
lower investment, and maintenance costs7,16 as the main
advantages of MSMPR crystallizers. Nevertheless, the reason-
ably longer start-up period, occurrence of product incon-
sistency (due to nonstable operation), problematic scale-up,
and low efficiency are disadvantageous compared to tubular
crystallizers.
In a conventionally operating MSMPR reactor system, the
product slurry is withdrawn continuously and the product
properties are generally the same as the agitated slurry. Usually,
peristaltic pumps are used for product removal; however, other
withdrawal techniques, such as “intermittent with-
drawal”,8,17−20 are becoming increasingly popular, which
prevents the blockage of the transfer lines. Using “intermittent
withdrawal”, approximately 10% of the slurry volume is
withdrawn in every one-tenth of residence time. Another
novel approach, the periodic MSMPR crystallizer21 was
designed by Powell et al., when no addition or withdrawal
to/from the crystallizer was applied between the suspension
transfer period, but the agitation remained constant. In that
work, the concept of the “state of controlled operation” was
investigated rather than “steady-state operation”. By imple-
menting periodic slurry transfer, more representative with-
drawal of the slurry could be achieved, while the possibility of
blockage and encrustation was reduced. These withdrawal
techniques usually employ peristaltic pumps22,23 or vac-
uum,8,18,24 though the former has a tendency to cause damage
to crystals. Other ways of continuous suspension withdrawal,
overflow techniques are presented just in a few publications
using vertical25 or lateral26,27 overflow tubes or pipes. These
could help to avoid the clogging of the transfer line and the
breaking of crystals, by eliminating the conventionally used
peristaltic pumps. As these instruments are different from
batch tank reactors, their implementation requires more
investments. This could be an explanation of their under-
representation in the literature.
Most of the continuous crystallizations discussed in the
literature started from the clear solution of arbitrary and mostly
high drug concentration.18,25,28,29 Processing of the steady-
state composition of a flow reaction mixture, containing
impurity byproducts, is challenging as the number of variable
parameters of crystallization is reduced. Just a few researchers
are concerned with this issue. For instance, Zhang et al.15
published the cooling/antisolvent continuous crystallization of
an API in a two-stage cascade MSMPR crystallizer. The feed
solution consisted of the API and impurities in the mixture of
ethyl acetate and water from a previous separation step, and
heptane was chosen as an antisolvent. Though pure materials
were used during the experiments, the composition of the feed
was the same as in the actual reaction mixture. This continuous
crystallization procedure was embedded in the publication of
Mascia et al.5 about the end-to-end manufacturing of aliskiren
hemifumarate. Adamo et al.30 also developed a compact,
reconfigurable end-to-end system, in which only a semibatch
crystallization step was used as the first part of the downstream
procedure. In another study, Richardo and Xiongwei31 set up a
cleaning protocol for vanisal sodium and aspirin production in
a continuous oscillatory baffled reactor (COBR). First, the
mentioned compounds were produced in one-step chemical
reactions in the first segment of the COBR, and then the drugs
were purified and separated through cooling crystallization in
the remaining baffled pipe sections of the COBR. The main
goal was to establish an effective cleaning method during the
transition between the production of different APIs and fine
chemicals. Accordingly, the yield and purity of the products
were characterized without examining the crystal size, habit,
and morphology.
Our work aimed to develop a continuous crystallization
technique adjusted to the end-to-end production line of
acetylsalicylic acid (ASA). For this purpose, the processing of a
reaction mixture was investigated using MSMPR crystallizer.
To avoid the use of a peristaltic pump at product withdrawal,
the crystallizer was equipped with overflow tubing and an
internal vertical plate served as a buffer element. It was also
required to produce large, homogeneous crystals with desired
purity being suitable for direct compression. Additionally, the
process parameter dependence of the yield, the product purity,
and also the crystal morphology had to be examined in detail.
The mixture was produced in a flow reactor according to a
method published recently by the authors.6 The mixture
contained the solvent, catalyzer, starting materials, and
secondary products of the synthesis.
2. EXPERIMENTAL MATERIALS AND METHODS
2.1. Materials. The solvent composition of the flow reaction
mixture can be found in Table 1. Acetylsalicylic acid (ASA, >99%)
and salicylic acid (SA, >99.0%) were obtained from Sigma-Aldrich.
The n-heptane (>96%) was purchased from Molar Chemicals. The
acetonitrile (ACN, >99.9%) used for the HPLC measurements was
obtained from Merck. The concentration of ASA in the reaction
mixture was 91.9 mg/mL or 0.097 g (ASA)/g (solvent mixture); the
SA impurity concentation was 4.84 mg/mL.
The feed solution was prepared by measuring the pure components
of the reaction mixture in a defined amount and stirring them until
complete dissolution of the solid compounds. Besides ASA, salicylic
acid (<3%), acetylsalicylic anhydride (<1%) were found in a <5%
amount during flow synthesis. Among the secondary products,
salicylic acid (SA) has the highest amount, and thus the impurities are
represented by 5% of SA. Antisolvent and combined cooling/
antisolvent crystallization of the flow reaction mixture was performed
in an MSMPR crystallizer as described in the following section.
2.1.1. Continuous Crystallization in the MSMPR Crystallizer. All
continuous crystallization experiments were performed in a 250 mL
jacketed glass reactor (DN 60, Schmizo, Schwitzerland) equipped
with a Eurostar power control-visc type stirrer (IKA, Germany) and a
PTFE coated Ruston 6-blade impeller with 35 mm overall dimensions
(horizontal). To control the temperature, a jacket temperature control
was used with a monofluid thermostat (Huber Ministat 230). The
temperature of the suspension was measured with a Pt-100
thermometer. The reactor system is illustrated in Figure 1. The
withdrawal of the slurry was obtained utilizing an overflow tubing;
hence, the discharge of the suspension was continuous and equivalent
to the feeding rate. A PTFE vertical plate, used as a buffer element,
was also placed in the reactor to separate the feed from the
withdrawal, hereby to ensure the uniform residence time distribution
Table 1. Purity, V/V Ratio, and Source of the Solvents in the
Reaction Mixture
purity V/V% source
Ethyl acetate (EtOAc) 79.5 Merck Millipore
Acetic acid (AcOH) 99−100% 16.3
Ethanol (EtOH) ≥99% 3.8
Phosphoric acid (H3PO4) 85 wt % 0.4
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of the crystals. The feed streams were dripped on the slurry agitated in
the reactor. The crystals had to dive under the plate to reach the
overflow tubing. The suspension was agitated with 700 rpm speed to
ensure representative or isokinetic withdrawal and avoid sedimenta-
tion of the crystals. The jacket temperature was set at 0 or 25 °C
resulting in 2.5 or 25 °C solution temperature that did not vary during
the whole process.
At the beginning of the experiments, 40 mL heptane was placed in
the empty reactor and was tempered at the desired temperature.
During agitation, 10 mL of the reaction mixture was pipetted to the
heptane to make a starting suspension. The ASA solvent and
antisolvent streams were dripped on this starting suspension. The feed
of the reaction mixture was performed with a JASCO PU-980 HPLC
pump, and Kappa 10PP single-piston isocratic pumps were used for
antisolvent intake. The product slurry flown out through the overflow
and the crystals were filtered directly using G2 or G3 glass filters
connected to a continuously operating water jet pump. The samples
were dried at room temperature without washing the filter cake.
During each experiment, we collected product samples at least 12
times for 5 to 20 min, depending on the residence time duration. The
experiments lasted for 20 residence times, as we intended to examine
the system after reaching steady-state conditions. Therefore, the
duration of experiments was 4, 8, or 16 h depending on the residence
time.
From just-filtered wet samples, HPLC samples were produced by
dissolving 1−5 mg of crystals in EtOH to make a 1 mg/mL
concentration solution. This solution was diluted with a mixture of
ACN:MeOH:H3PO4 (85%) (92:8:0.5 v/v ratio) to reach 1:20
dilution. The filters with samples were weighed after drying at
room temperature to calculate the yield. The yield calculation was
based on the total ASA content (mf, g), that was determined with the
following equation:
= × ̇ ×m t V cf f s (1)
where tf is sampling duration in minutes, V̇s is the flow rate of ASA
solution feed in mL/min, and c is the ASA concentration of the
solution in g/mL.
The process parameters of the continuous crystallization experi-
ments are found in Table 2. The order of the experiments from
MSMPR_3 to MSMPR_8 were randomized.
2.2. Methods. 2.2.1. Determination of the Solubility of ASA.
The solubility of the ASA in the reaction mixture was studied in a
jacketed glass reactor (150 mL, Normag, Germany) equipped with a
Pt-100 thermometer, a Eurostar power control-visc type stirrer (IKA,
Germany), a propeller mixer, and a monofluid thermostat. The speed
value of the stirrer was set at 200 rpm, and the slurry was tempered at
1, 13, and 25 °C to measure the solubility in the temperature range of
continuous crystallization experiments.
The ASA solubility in the solvent mixture (see in Table 1) was
examined as a function of temperature and antisolvent to ASA
solution ratio. The conditions of the solubility experiments are
detailed in Table 3. Primarily, the exact amounts of the solvent
mixture and the heptane were poured into the glass reactor and
cooled to 1 °C starting temperature. When the desired temperature
was achieved, solid ASA was added to the mixture. The amount of
ASA added was more than the expected saturation concentration
providing a heterogenic system. An estimation of the amount of solid
ASA in the slurry was placed in Supporting Information. The slurry
was kept agitated for at least 1 h to achieve the equilibrium state. After
1 h of agitation, some volume of the sample was taken and was filtered
through a PTFE syringe filter (0.45 μm) to reach the saturated ASA
solution. These ASA solutions were diluted 100 and 1000 times,
dissolved and extracted with a mixture of ACN:MeOH:H3PO4 (85%)
(92:8:0.5 v/v ratio) due to ensure the chemical stability of ASA32
until the HPLC measurement. The concentration of ASA was
determined using RP-HPLC. After the first sample, the slurry in the
vessel was heated to 13 °C and sampled after an hour of stirring. This
procedure was repeated at 25 °C.
2.2.2. HPLC Analysis. The solubility of ASA and the purity of the
product were investigated with an RP-HPLC (Agilent 1200 series LC
System) according to the method that was used to determine the
purity of the ASA reaction mixture after the synthesis by Balogh and
his co-workers.6 During this process, a 5 μL sample volume was
injected onto a Supelco Inertsil ODS-2 C18 column (5 μm; 250 × 4.6
mm). Isocratic elution was performed using an eluent containing 60%
Figure 1. Schematic image of the experimental setup.
Table 2. Experimental Conditions of Continuous Crystallization Experiments
ID of experiment
temperature
[°C] ASA solution feed flow rate [mL/min] heptane feed flow rate [mL/min] residence time [min] overall time of exp. [h]
MSMPR_1 12.0 2 8 23.50 4.09
MSMPR_2 25.0 2 8 23.50 4.29
MSMPR_3 2.5 4 16 11.75 4.00
MSMPR_4 2.5 2 8 23.50 7.95
MSMPR_5 2.5 1 4 47.00 15.93
MSMPR_6 25.0 4 16 11.75 4.00
MSMPR_7 25.0 2 8 23.50 7.95
MSMPR_8 25.0 1 4 47.00 16.02













SE_1 70.0 0.0 - 9.140
SE_2 33.0 66.0 2/1 3.003
SE_3 20.0 80.0 4/1 2.068
SE_4 14.5 87.7 6/1 1.400
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ACN and 40% water−phosphoric acid mixture (200:1 ratio). The
measurement lasts 4 min; the retention time of ASA and SA is at 2.5
and 3.1 min, respectively. The exact ASA concentration measurement
was based on the sum of the ASA and the impurity SA peak areas. The
impurity content of the crystalline product was determined based on
the ratio of the peak areas.
2.2.3. Particle Size Distribution and Visual Measurement. The
particle size distribution (PSD) was measured offline using a Parsum
IPP 70-s inline particle sizing probe in batch mode. The samples were
dispersed into the probe for estimating the cord length of the crystals.
The volumetric distribution values Dv10, Dv50, and Dv90 were applied
to characterize the crystal size distribution (CSD) of the products.
The CSD plots represent volume-based distributions where crystal
size intervals are plotted as a function of the volume fraction (%). The
volume fraction (%) of xi crystal size interval represents the volume
percent of these crystals relative to the total crystal fraction. The
crystal habit of the products was monitored by using a CKX53 inverse
microscope equipped with an 18Mp CAM-SC180 Camera set.
3. RESULTS AND DISCUSSION
3.1. Solubility Measurement. Based on the results of the
preliminary batch experiments, heptane was chosen as an
effective antisolvent for ASA crystallization. In further batch
experiments, the effect of antisolvent to ASA solution ratio,
residence time, and temperature on the yield and product
purity were studied. Details of these batch experiments are in
the Supporting Information.
The solubility of the ASA in the exact composition of the
reaction mixture and also in the presence of heptane
antisolvent was measured at three temperatures (1, 13, 25
°C). The determined saturation concentrations are presented
in Figure 2.
The blue points represent the saturation of ASA in the
solvent composition of the pure reaction mixture. This
saturation curve indicates a slight dependence of solubility as
a function of temperature; thus, cooling itself is not enough for
reaching reasonable yield. The red line represents the ASA
concentration in the initial reaction mixture (91.9 mg/mL),
which is a near-saturated solution based on the saturation data
at room temperature. The orange, green, and purple points
represent the 2:1, 4:1, and 6:1 heptane to ASA solution v/v
ratio, consecutively. The results highlight that the antisolvent
significantly affects the solubility of ASA in the reaction
mixture. Moreover, the increasing amount of antisolvent results
in higher supersaturation, which leads to better productivity as
well. Considering the productivity and economic aspects,
antisolvent and combined cooling/antisolvent crystallization
were implemented at 4:1 heptane to ASA solution ratio.
3.2. Position of the Buffer Element. A vertical plate as a
buffer element was placed in the reactor to ensure
homogeneous slurry withdrawal. The schematic images of
the applied buffer element positions are illustrated in Figure 3.
The position of the vertical plate affects the efficacy of product
withdrawal. By appling position A, the number of crystals in
the withdrawn slurry was representative at the beginning of the
experiment, whereas later the quantity of the discharged
crystals was not sufficient. During the start-up phase, the
density in the reactor tends to increase, while the yield is
decreasing. The explanation for this phenomenon is that the
smaller crystals produced in the beginning are removable
easily. However, growing crystals are more likely to cause
sedimentation problems, so ensuring efficient mixing con-
ditions is essential. In MSMPR_1, the steady-state conditions
were not achieved, as the product withdrawal was not
representative. The amount and the quality of removed
crystals were not the same as the solids agitated in the reactor.
In contrast, by utilizing position B, the yield remains almost
constant (see in Figure 4). Consequently, we used position B
for further continuous crystallization to provide representative
product removal.
It was observed that the product quality similar in the
absence of the buffer element as well. Thus, the applied buffer
element did not affect the crystallization process significantly.
Additionally, the buffer element was necessary for representa-
tive product removal.
3.3. Evaluation of the Product Quality. 3.3.1. Charac-
terization of the Product Purity, the Process Yield, and
Productivity. A series of experiments has been conducted to
investigate the changes in the product features (i.e., purity,
crystal size distribution, crystal habit) and process productivity
Figure 2. Solubility of ASA in the reaction mixture without heptane,
with 2:1, 4:1, and 6:1 heptane to ASA solution v/v ratio. The
concentration of ASA in the reaction mixture (red line, 91.9 mg/mL).
Figure 3. Schematic upward images of buffer element position A and
position B.
Figure 4. Yield during MSMPR_1 (position A) and MSMPR_2
(position B).
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by varying the process parameters. In the following section, the
results of the process characterization will be detailed.
The onset of steady-state operation was detected by
analyzing the crystal morphology, namely, the crystal habit,
crystal size, and CSD. The steady-state operation could be
observed after the crystallization procedure has already lasted
for six to ten residence times in each of the experiments
independently of the adjusted process parameters. After
reaching the steady-state operation, stable product quality
and quantity were achieved. The removed product was
representative, since the crystal size, CSD, and crystal habit
of the sampling and the reactor content were determined
straight after the sampling proved to be the same.
In terms of purity, the SA content was less than 0.81% in
each experiment. The average impurity of the products was
0.30 ± 0.16% evidenced by HPLC measurement; thus, the
developed direct processing technique is proper for cleaning
the reaction mixture from undesired impurities. Meeting the
3% regulatory limit is achievable when this technique is used.
In Figure 5, it is shown that in the examined design space the
process parameters do not affect the dispersion of the impurity
content significantly. It can be assumed that SA remains
dissolved in the mother liquor. As the filter cake was not
washed, the source of the product SA content could be the
mother liquor adhered to the crystal surface. To decrease SA
concentration, an adequate washing procedure could be
developed for this system to eliminate the adhered mother
liquor from the surface of the filter cake.
The continuous crystallization experiments were charac-
terized by yield and productivity. We calculated the yield of the
samplings (ys,X, %) from the weight of dry crystalline product
samples (ms, g) and the fed ASA amount (mf, g) estimated
from the length of the sampling (tf), ASA solution flow rate







After placing the inner vertical plate in position B, almost
constant yields were obtained from the beginning of the
experiments. Hence, each experiment could be featured by the
average yield (yAv, %) and its standard deviation (St. dev. %)




















where n is the number of samples [-], and y̅ is the mean value
of the yield in %.
The values of yield and process productivity can be shown in
Table 4.
As can be seen in Table 4, lower temperature resulted in a
significant increase in yield, while residence time had no
remarkable effect on the product quantity. In most of the
experiments, the standard deviation of yield remained under
4%. The highest standard deviation regarding yield was 6% in
the MSMPR_7 (T: 25 °C, RT: 23.5 min) experiment.
It is important to mention that several conditions could
potentially alter the yield by applying an overflow and vertical
plate. Some examples are as follows: (1) the variation in feed
flow rate caused by the inefficiently operated pumps; (2) the
deposition and the detachment of the crystals on/from the
reactor wall or on/from the surface of the vertical plate; (3) the
position of feeding tubes. If these tubes were placed close to
the wall or each other, it could result in local inhomogeneity in
concentration intensifying the deposition mechanisms. We
experienced these events during the process development and
made an effort to eliminate all these contingencies in the
presented results.
The productivity of the experiments varied in the range of
3.2−17.3 g/h. Shorter residence time and lower temperatures
favor an increase in productivity. Hence, the highest
productivity could be obtained when the residence time is
shorter (11.75 min), but the yield is high as a result of the
lower operating temperature (78.6 ± 2.8%).
3.3.2. Alteration of Crystal Morphology. To monitor the
main tendency in crystal morphology changes during MSMPR
crystallizations, two processes are demonstrated. All process
parameters of the selected experiments are different, as it can
illustrate the difference caused by varying operating circum-
stances. In Table 5, Table 6, and Table 7, two selected
crystallizations are described by evaluating the samples with
Dv10, Dv50, Dv90, and D[4,3] values, boxplot diagrams,
microscopic pictures, and particle size distribution. The
volume mean diameters (D[4,3]), presented besides Dv values,
are generally suitable for the description of polydisperse
systems. In this case, the volume mean diameter was similar to
Dv50.
The ASA solution and antisolvent were fed into the initial
suspension; thus, secondary nucleation occurred during the
continuous process. After one residence time, the product
crystals were significantly smaller and less columnar at low
temperature (2.5 °C, Dv50: 306 μm), while at room
Figure 5. Box-plot diagram of SA impurity content of the products.
Table 4. Summary of the MSMPR Crystallization







time [min] yield [%]
productivity
[g/h]
MSMPR_3 2.5 11.75 78.6 ± 2.8 17.3
MSMPR_4 2.5 23.50 74.1 ± 3.2 8.2
MSMPR_5 2.5 47.00 76.8 ± 3.7 4.2
MSMPR_6 25.0 11.75 59.2 ± 2.7 13.1
MSMPR_7 25.0 23.50 64.4 ± 6.1 7.1
MSMPR_8 25.0 47.00 57.6 ± 5.8 3.2
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temperature the product contained large (Dv50:707 μm)
columnar crystals that were growing in all directions. During
the first phase of both experiments, the crystals were growing
and the CSDs were broadening. Before the onset of steady-
state operation, reaching the critical size for more than five and
seven residence times, the crystals started to fragment. This led
to an increase in the amount of smaller crystal fraction. This
mechanism could be monitored on the microscopic pictures
and the boxplot graphics at both studied temperatures. The
steady-state conditions were reached in both processes after
more than eight residence times. Most of the large columnar
particles were transformed into spherical and isometric crystals.
At low operation temperature, the product was polydisperse
with two characteristic crystal fractions, while at room
temperature, the manufactured crystals were unimodal,
according to the volumetric distributions.
A similar process was identified by examining the boxplot
diagram. Smaller crystals and narrower CSD were established
at lower temperatures. The product size and CSD were
growing and broadening for a certain crystal size when
Table 5. Comparison of MSMPR_3 (2.5 °C, 11.75 min) and MSMPR_8 (25 °C, 47 min) Experiment Regarding Crystal Size
Alteration during the Crystallization Process
Table 6. Microscopic Pictures (4×), Dv Values, and CSD Plots of the MSMPR_3 Samples (1 RT, 10 RT, and from the Reactor
at the End of the Experiment)
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Table 7. Microscopic Pictures (4×), Dv Values, and CSD Plots of the MSMPR_8 Samples (1 RT, 10 RT, and from the Reactor
at the End of the Experiment)
Table 8. Summary of the MSMPR Crystallization Experiments at 2.5 °C Regarding Crystal Habit, Crystal Size, and Crystal Size
Distribution of the Experiments under Steady-State Operation
Table 9. Summary of the MSMPR Crystallization Experiments at 25 °C Regarding Crystal Habit, Crystal Size, and Crystal Size
Distribution of the Experiments under Steady-State Operation
Crystal Growth & Design pubs.acs.org/crystal Article
https://dx.doi.org/10.1021/acs.cgd.0c00252
Cryst. Growth Des. 2020, 20, 4433−4442
4439
disintegration became dominant. When the temperature was
set at 2.5 °C the majority of the particles were small; however,
a great amount of significantly larger crystals (outliers and
extremes >75%) were detected in steady-state operation. At
room temperature, in contrast, the distributions of the outliers
and extremes were smaller.
3.3.3. Particle Size Distribution. In Table 8 and Table 9, the
microscopic images, the average values, and the standard
deviation of Dv10, Dv50, and Dv90, and the volume density
distributions of the output are presented to illustrate the effect
of studied temperatures and residence times on CSD. At 2.5
°C, the supersaturation was higher compared to higher
operation temperatures, and thus nucleation dominated during
the crystallization process resulting in smaller crystals. As
already established, a few large isometric crystals were
identified at the beginning of the process. These crystals
could be either grown and resulted in crystals with rounded
surface or aggregates bounding smaller particles on the surface
with time. At 2.5 °C, large size differences could be observed
among the produced crystal fractions as a function of
decreasing residence time, which accelerated the particle
sedimentation. As a result, the products were polydisperse
with a broad CSD curve, especially when shorter residence
time was set (Dv10: 83 ± 19 μm; Dv90: 577 ± 95 μm). In
contrast, lower supersaturation could be achieved at room
temperature. Hence, the crystal growth rate could be higher,
resulting in wide unimodal crystal size distribution. It was
found that the length of the residence time does not change
the quality of the crystalline product significantly in the
investigated residence time range. Consequently, it was
evidenced that the main differentiator was the temperature,
as the residence time effect was not significant.
The following steps of processing the large, isometric, and
uniform particles with good flowability are preferred for the
pharmaceutical formulation. In contrast, polydispersity in the
product leads to the separation of fractions that is undesired in
tableting steps. Previous investigations of the starting material
by the authors confirmed that the presence of needle-shaped or
columnar crystals, smaller than 75 μm, worsens the flowability
of particles below the level needed for direct compression.
Further details of this investigation are presented in the
Supporting Information. Accordingly, the ratio of this fraction
was investigated and shown in Figure 6. At 2.5 °C, the amount
of these small crystals increased up to 12 v/v%. At 25 °C, as
low as 0.5 v/v% small-sized fractions could be achieved, which
assists better flowability. Consequently, longer residence time
and higher temperatures provide better product quality in the
aspect of the formulation procedure of the crystals.
4. CONCLUSION
Most of the published continuous crystallization studies focus
on the crystallization of a product from pure drug solution. We
developed, in contrast, the continuous crystallization of a
complex, multicomponent reaction mixture. For this purpose,
MSMPR crystallizer was equipped with an overflow tube for
product removal and an inner vertical plate as a buffer element
to prevent the immediate elimination of the fed materials and
also ensure the representative withdrawal of the produced
polydisperse crystals. The formation of polydisperse products
was also observed in the absence of the buffer element. The
buffer element was necessary for representative product
removal of the produced polydisperse crystals.
The effect of the position of the buffer element on product
withdrawal efficacy was investigated. It was found that the
position parallel to the outlet tubing supports constant crystal
withdrawal independently of crystal size and CSD. It has been
proven that using pump-free solutions like overflow piper or
tubes for product withdrawal could be an effective alternative
of conventional peristaltic pumps. Further advantages of using
this technology are that the difficulties of level control and
plugging issues during product removal could be eliminated.
System operations are more cost-effective, since fewer pumps
are required for material transfer leading to lower investment
and operational costs.
Furthermore, the effect of temperature and length of
residence time on product quality (purity, crystal habit, and
CSD) and quantity was examined. The significant impact of
temperature on yield, crystal size, and CSD has been detected,
but no effect on product impurity content was found.
Consequently, yield could be increased by decreasing the
operating temperature. Furthermore, the average SA impurity
content was 0.3%, far below the 3% regulatory limit. The low
temperature (2.5 °C) favored the generation of a smaller
crystal fraction due to higher supersaturation. Polydisperse
products could be characterized by a wide and multimodal
CSD. By appling higher temperatures (25 °C), large crystals
with unimodal distribution could be produced. The length of
the residence time had no significant effect on the examined
product parameters in the investigated residence time range.
Additionally, in accordance with the preliminary batch
experiments presented in the Supporting Information, the
kinetics of the investigated crystallization system was rather
fast. Due to the fast kinetics of this system, the tubular
crystallizer could be suitable for crystallization as well.
In conclusion, separation and purification of ASA from a
multicomponent reaction mixture could be performed based
on the developed continuous crystallization process utilizing a
single-stage MSMPR crystallizer. Investigating the relation
between the process parameters and the product quality, we
found that by increasing the operating temperature to 25 °C
the obtained particles of unimodal crystal size distribution
could be more adequate for the subsequent formulation steps
of the crystalline product. Therefore, the developed continuous
crystallization method can be integrated well into the end-to-
end production chain.Figure 6. V/V% of particles sized 75 μm or smaller.
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